Hemophilia News Today Home | Hemophilia News Today
2024年11月22日 · Hympavzi approved in EU for hemophilia A, B, without inhibitors. Pfizer’s Hympavzi (marstacimab) has been approved in the European Union (EU) to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with severe hemophilia A or hemophilia B who weigh at least 35 kg (77 pounds) and haven’t developed neutralizing…
News Archives - Hemophilia News Today
Hympavzi approved in EU for hemophilia A, B, without inhibitors. Pfizer’s Hympavzi (marstacimab) has been approved in the European Union (EU) to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with severe hemophilia A or hemophilia B who weigh at least 35 kg (77 pounds) and haven’t developed neutralizing…
Prophylaxis is able to reduce bleeds from severe hemophilia in...
2024年9月27日 · Annualized bleed rate reduced. Researchers analyzed four clinical trials involving patients with severe hemophilia A and B, ages 50 and older, who received treatment with extended half-life products to better understand the impact of prophylaxis when introduced later in life.. The hemophilia A patients had taken part in A-LONG (NCT01181128) and its ASPIRE (NCT01454739) extension study, while ...
A new year brings hope for the treatment of hemophilia
2023年12月29日 · Embracing the start of 2024, I reflect on the friendships I’ve made within the hemophilia community over the past year. As a woman navigating the complexities of hemophilia B and von Willebrand disease, these connections have become a source of strength and solidarity for me.Each person I’ve encountered embodies resilience, and collectively we stand as a testament to the unwavering spirit ...
Hemgenix Gene Therapy Benefits Sustained for 2 Years in Phase 3...
2022年12月14日 · As previously described, this main goal was met, with annualized bleeding rates dropping by 64% seven to 18 months after infusion compared with the lead-in period.Moreover, FIX activity levels were significantly increased to about 37% of normal levels. Two-year findings were largely similar, demonstrating a consistent and sustained effect of …
Marstacimab lowered bleed rates in hemophilia in Phase 3 trial
2023年5月31日 · In so doing, it met the main goal of the pivotal Phase 3 BASIS clinical trial, designed to evaluate the treatment’s effectiveness in preventing bleeds in these two main types of hemophilia.. Pfizer, the therapy’s developer, plans to discuss these Phase 3 data with regulatory authorities in the coming months and begin the process of …
Hemophilia treatment options | Hemophilia News Today
2024年10月22日 · Hemophilia is caused by the lack of certain clotting factors, which are proteins normally needed for blood to clot.Factor replacement therapies, which involve administering a working version of the missing clotting protein, are generally considered the gold standard for …
Partners will work to further gene-editing treatment for …
2023年11月10日 · The partners will seek to advance a treatment involving gene editing — used to correct, add, or delete a DNA sequence — for the bleeding disorder. “We are thrilled to work with Novo Nordisk in the development of a potentially transformative gene editing treatment for a patient population in need of novel therapeutic approaches,” Pete Lutwyche, PhD, Genevant’s president and CEO, said ...
What is hemophilia? | Hemophilia News Today
2024年5月7日 · Hemophilia treatment. The main treatments used in hemophilia A and B are factor replacement therapies that contain a working version of the missing clotting factor. Such treatments can be given to patients on demand, to control active bleeds, or prophylactically, meaning preventively, to reduce the frequency and the risk of bleeds.
Top 10 Hemophilia Stories of 2021 - Hemophilia News Today
2022年1月7日 · Positive preclinical data on Roctavian (valoctocogene roxaparvovec), a gene therapy candidate for hemophilia A, was presented in May by its developer, BioMarin Pharmaceutical.Given through a single into-the-vein (intravenous) infusion, Roctavian is designed to use a modified, harmless AAV to deliver a working copy of the F8 gene to liver cells. That working F8 gene is expected to restore FVIII ...